Published Online
on January 6, 2009

A more recent version of this article appeared on January 1, 2009

This Article Full Text (PDF) Data Supplement All Versions of this Article: 2/1/16    most recent CIRCOUTCOMES.108.807123v2 CIRCOUTCOMES.108.807123v1 Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, P. S. Articles by Chow, T. Search for Related Content PubMed PubMed Citation Articles by Chan, P. S. Articles by Chow, T. Related Collections Related Articles

Original Article

Impact of Age and Medical Comorbidity on the Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention

Paul S. Chan, MD, MSc; Brahmajee K. Nallamothu, MD, MPH; John A. Spertus, MD, MPH; Frederick A. Masoudi, MD, MSPH; Cheryl Bartone, BS, MPH; Dean J. Kereiakes, MD and Theodore Chow, MD

From the Mid-America Heart Institute and University of Missouri (P.S.C., J.A.S.), Kansas City, Mo; The VA Ann Arbor Health Services Research and Development Center of Excellence and the University of Michigan Division of Cardiovascular Medicine (B.K.N.), Ann Arbor, Mich; Division of Cardiology (F.A.M.), Denver Health Medical Center and the University of Colorado at Denver and Health Sciences Center, Denver, Colo; and The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center (C.B., D.J.K., T.C.), Cincinnati, Ohio.

Background: Although implantable cardioverter-defibrillators (ICDs) reduce mortality in primary prevention patients with left ventricular systolic dysfunction, recent studies have questioned their overall role in clinical practice, especially in older patients and those with major comorbid conditions.

Methods and Results: In a prospective cohort of 965 patients with ischemic and nonischemic cardiomyopathies (ejection fraction 35%) and no prior ventricular arrhythmias, we compared long-term mortality in patients who did (n=494 [51%]) and did not receive ICDs over a mean follow-up period of 34+16 months. Using a landmark analysis, multivariable Cox proportional hazards models that included propensity scores for ICD implantation assessed the relationship between ICD therapy and mortality in the entire cohort and by age and the presence of major comorbid conditions. Data from these analyses were then used as inputs in a Markov model to generate incremental cost-effectiveness ratios for ICD therapy. Patients who received ICDs were similar in age and prevalence of most major comorbid conditions, including symptomatic heart failure. After multivariable adjustment, ICD therapy was associated with a 31% lower risk for all-cause mortality (adjusted hazard ratio, 0.69; 95% CI, 0.50 to 0.96; P=0.03). The relationship between ICD therapy and lower all-cause mortality was consistent after stratification by age (<65, 65 to 74, and 75), ischemic etiology, ejection fraction (>25% versus 25%), and the presence of major comorbid conditions (probability values for all interactions >0.05). Incremental cost-effectiveness ratios for ICD therapy were similar between patients aged 75 years and younger patients but rose slightly in those with multiple comorbid conditions.

Conclusions: Routine use of ICDs in primary prevention patients with left ventricular systolic dysfunction was associated with lower all-cause mortality, even among older patients and those with major comorbid conditions. Although their use needs to be individualized, our findings suggest that these groups should not be routinely excluded from ICD treatment.

Related Articles

Is Anyone Too Old for an Implantable Cardioverter-Defibrillator?

Paul A. Heidenreich and Vivian Tsai
Circ Cardiovasc Qual Outcomes 2009 2: 6-8. [Extract] [Full Text] [PDF]

Impact of Age and Medical Comorbidity on the Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention

Paul S. Chan, Brahmajee K. Nallamothu, John A. Spertus, Frederick A. Masoudi, Cheryl Bartone, Dean J. Kereiakes, and Theodore Chow
Circ Cardiovasc Qual Outcomes 2009 2: 16-24. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				A. F. Hernandez, G. C. Fonarow, B. G. Hammill, S. M. Al-Khatib, C. W. Yancy, C. M. O'Connor, K. A. Schulman, E. D. Peterson, and L. H. Curtis Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Circ Heart Fail, January 1, 2010; 3(1): 7 - 13. [Abstract] [Full Text] [PDF]

				M. R. Cowie and on behalf of the co-authors Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe? Europace, October 1, 2009; 11(10): 1407 - 1408. [Full Text] [PDF]

				H. M. Krumholz One Year at Circulation: Cardiovascular Quality and Outcomes Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 399 - 401. [Full Text] [PDF]

				H. M. Krumholz Outcomes Research: Myths and Realities Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 1 - 3. [Full Text] [PDF]

				P. A. Heidenreich and V. Tsai Is Anyone Too Old for an Implantable Cardioverter-Defibrillator? Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 6 - 8. [Full Text] [PDF]